A phase I and randomised phase II study of docetaxel and RAD001 (everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck.

Trial Profile

A phase I and randomised phase II study of docetaxel and RAD001 (everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Docetaxel (Primary) ; Everolimus (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DORA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 May 2012 Actual end date changed from Aug 2009 to 12 Apr 2011 as reported by UKCRN.
    • 31 May 2012 Status changed from recruiting to completed as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top